Acova

Acova is a brand name of argatroban, approved by the FDA in the following formulation(s):

ACOVA (argatroban - injectable; injection)

• 
  Manufacturer: PFIZER
  
  Approval date: June 30, 2000
  
  Strength(s): 250MG/2.5ML (100MG/ML) ^[RLD][AP]

Has a generic version of Acova been approved?

A generic version of Acova has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Acova and have been approved by the FDA:

argatroban injectable; injection

• 
  Manufacturer: HIKMA PHARM CO LTD
  
  Approval date: January 5, 2012
  
  Strength(s): 250MG/2.5ML (100MG/ML) ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for dissolving arginineamides and pharmaceutical compositions containing them
  Patent 5,214,052
  Issued: May 25, 1993
  Inventor(s): Ofuchi; Kunihiko & Nomura; Tatsuo
  Assignee(s): Mitsubishi Kasei Corporation
  A method for dissolving an arginineamide of the invention comprising dissolving N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I) ##STR1## wherein R.sup.1 represents a (2R, 4R)-4-alkyl-2-carboxypiperizino group and R.sup.2 represents a phenyl group or a condensed polycyclic compound residue which may be substituted with one or more substituents selected from lower alkyl groups, lower alkoxy groups and lower alkyl-substituted amino groups, said condensed polycyclic compound residue including a benzene ring which binds to sulfur atom of the sulfonyl group in the general formula (I) and is condensed with one or more other rings which may be heterocyclic and having 7 to 14 carbon atoms as the ring-constituent atoms; and/or its salt in a solvent of alcohol and water is disclosed herein. And, the pharmaceutical composition comprising N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I), an alcohol and water is disclosed herein.
  
  Patent expiration dates:
  
  
  • June 30, 2014
    
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 5, 2011 - PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
  
  

See also...

• Acova Consumer Information (Cerner Multum)
• Acova AHFS DI Monographs (ASHP)
• Argatroban Consumer Information (Wolters Kluwer)
• Argatroban Consumer Information (Cerner Multum)
• Argatroban Intravenous Advanced Consumer Information (Micromedex)
• Argatroban AHFS DI Monographs (ASHP)